<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00242294</url>
  </required_header>
  <id_info>
    <org_study_id>APTA-2217-06</org_study_id>
    <nct_id>NCT00242294</nct_id>
  </id_info>
  <brief_title>Efficacy and Safety of Roflumilast in Japanese Patients Older Than 40 Years With Chronic Obstructive Pulmonary Disease (APTA-2217-06)</brief_title>
  <official_title>A Confirmatory Study of APTA-2217 in Patients With Chronic Obstructive Pulmonary Disease (A Placebo-controlled Double-blind Comparative Study)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AstraZeneca</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Mitsubishi Tanabe Pharma Corporation</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>AstraZeneca</source>
  <brief_summary>
    <textblock>
      The aim of the study is to investigate the effect of roflumilast (APTA-2217) on lung function
      in patients with chronic obstructive pulmonary disease (COPD). Roflumilast will be
      administered orally once daily. The study duration consists of a baseline period (4 weeks)
      and a treatment period (24 weeks). The study will provide further data on safety,
      tolerability, and effectiveness of roflumilast.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>November 2004</start_date>
  <completion_date type="Actual">March 2007</completion_date>
  <primary_completion_date type="Actual">September 2006</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double</masking>
  </study_design_info>
  <primary_outcome>
    <measure>change in lung function parameters (post-bronchodilator).</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>pulmonary function test, COPD symptoms, rescue medication, evaluation of QOL, COPD exacerbation, adverse events, pharmacokinetics.</measure>
  </secondary_outcome>
  <enrollment>570</enrollment>
  <condition>Chronic Obstructive Pulmonary Disease (COPD)</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Roflumilast</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Main inclusion criteria:

          -  Patients with chronic obstructive pulmonary disease

          -  Current smoker or ex-smoker

          -  30 to 80% of predicted FEV1 after inhalation of short acting beta stimulant

        Main exclusion criteria:

          -  Patients with poorly controlled COPD

          -  Patients who need for long-term oxygen therapy

          -  Patients who have concurrent respiratory diseases such as asthma, diffuse
             panbronchiolitis, congenital sinobronchial syndrome, bronchiolitis obliterans,
             bronchiectasis, active tuberculosis, pneumoconiosis, pulmonary lymph vascular myoma,
             which are considered to affect the evaluation
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
  </eligibility>
  <overall_official>
    <last_name>AstraZeneca AstraZeneca</last_name>
    <role>Study Director</role>
    <affiliation>AstraZeneca</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Nycomed Japan and Mitsubishi Tanabe Oharma Corporation</name>
      <address>
        <city>Osaka</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <link>
    <url>http://filehosting.pharmacm.com/DownloadService.ashx?client=CTR_MED_7111&amp;studyid=4466&amp;filename=APTA-2217-06-RDS-2008-12-05.pdf</url>
    <description>APTA-2217-06-RDS-2008-12-05.pdf</description>
  </link>
  <verification_date>September 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 19, 2005</study_first_submitted>
  <study_first_submitted_qc>October 19, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 20, 2005</study_first_posted>
  <last_update_submitted>October 24, 2016</last_update_submitted>
  <last_update_submitted_qc>October 24, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 26, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>COPD</keyword>
  <keyword>Phosphodiesterase 4 inhibitor</keyword>
  <keyword>Roflumilast</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Diseases</mesh_term>
    <mesh_term>Lung Diseases, Obstructive</mesh_term>
    <mesh_term>Pulmonary Disease, Chronic Obstructive</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

